EnteroMedics Inc. (NASDAQ:ETRM) was upgraded by equities researchers at ValuEngine from a “strong sell” rating to a “sell” rating in a report released on Friday.

ETRM has been the topic of a number of other research reports. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and issued a $11.00 target price on shares of EnteroMedics in a research report on Thursday, May 25th. Zacks Investment Research raised shares of EnteroMedics from a “hold” rating to a “strong-buy” rating and set a $2.25 target price on the stock in a research report on Wednesday, August 23rd.

EnteroMedics (NASDAQ:ETRM) traded down 2.12% on Friday, reaching $1.85. 236,800 shares of the company traded hands. EnteroMedics has a 1-year low of $1.75 and a 1-year high of $30.41. The stock’s market capitalization is $15.34 million. The stock has a 50 day moving average of $3.16 and a 200-day moving average of $4.79.

EnteroMedics (NASDAQ:ETRM) last posted its earnings results on Tuesday, August 8th. The medical device company reported ($0.91) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.00) by $0.09. EnteroMedics had a negative net margin of 4,399.48% and a negative return on equity of 167.73%. The company had revenue of $0.09 million for the quarter, compared to analysts’ expectations of $0.20 million. On average, equities analysts anticipate that EnteroMedics will post ($3.02) EPS for the current year.

COPYRIGHT VIOLATION WARNING: “EnteroMedics Inc. (ETRM) Stock Rating Upgraded by ValuEngine” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.thecerbatgem.com/2017/09/02/enteromedics-inc-etrm-stock-rating-upgraded-by-valuengine.html.

An institutional investor recently raised its position in EnteroMedics stock. Vanguard Group Inc. raised its position in EnteroMedics Inc. (NASDAQ:ETRM) by 24.3% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 49,740 shares of the medical device company’s stock after buying an additional 9,727 shares during the period. Vanguard Group Inc. owned approximately 0.72% of EnteroMedics worth $248,000 at the end of the most recent reporting period. 1.27% of the stock is currently owned by hedge funds and other institutional investors.

EnteroMedics Company Profile

EnteroMedics Inc (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve.

Receive News & Stock Ratings for EnteroMedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EnteroMedics Inc. and related stocks with our FREE daily email newsletter.